Endocrine Abstracts

Cinacalcet decreases and normalizes serum calcium levels across a broad severity range of primary hyperparathyroidism (PHPT), slightly reduces parathyroid hormone levels which generally remains elevated, whereas it has no effect on bone mineral density (BMD). Therefore, when administering Cinacalcet to a patient with PHPT, concomitant treatment with an anti-catabolic drug should be considered.An open-labeled, prospective trial was conducted in 30 patient...

Introduction: Bariatric surgery has important metabolic complications such as bone mass loss.Goal: To assess bone mineral density (BMD) after Roux-en-Y gastric by-pass (RYGB) in patients under standard calcium and vitamin D supplementation.Method: In patients with morbid obesity submitted to RYGB, we measured BMD with a dual X-ray densitometer. Using World Health Organization (WHO) criteria’s, values were compared with young c...

Background: Acromegaly is the consequence of excessive growth hormone (GH) secretion, usually produced by a pituitary adenoma. In the last years, statins have been implicated in the response to treatment of patients with acromegaly. Although this fact is not very clear.Objective: To analyze whether pretreatment with statins modifies the adenoma molecular phenotype of the acromegalic patients and how this changes could help to influence the response to tr...

Background: Cushing’s syndrome (CS) is considered to be more frequent among patients with metabolic syndrome. Previous studies have suggested to perform a routine screening for CS in obese patients; however, more recent reports only recommend a case-finding approach in patients with uncontrolled diabetes and hypertension, despite appropriate treatment.Objective: The aim of this study was to evaluate the prevalence of unsuspected CS in morbidly obese...